Literature DB >> 12708132

Copper and ceruloplasmin status in serum of prostate and colon cancer patients.

Shivananda B Nayak1, Vinutha R Bhat, Dinesh Upadhyay, Saraswati L Udupa.   

Abstract

Serum copper and ceruloplasmin levels were estimated in 20 patients each of prostate and colon cancer. Although copper to ceruloplasmin ratio was not significantly altered, copper and ceruloplasmin levels were increased significantly in the cancer patients as compared to controls. Trace elements and free radicals have been implicated in the etiology of cancer. Hence determination of specific antioxidants (like ceruloplasmin) and trace elements (like copper) may be of value in the early diagnosis of prostate and colon cancer.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12708132

Source DB:  PubMed          Journal:  Indian J Physiol Pharmacol        ISSN： 0019-5499


  30 in total

1.  Disulfiram treatment facilitates phosphoinositide 3-kinase inhibition in human breast cancer cells in vitro and in vivo.

Authors:  Haijun Zhang; Di Chen; Jonathan Ringler; Wei Chen; Qiuzhi Cindy Cui; Stephen P Ethier; Q Ping Dou; Guojun Wu
Journal:  Cancer Res       Date:  2010-04-27       Impact factor: 12.701

2.  A novel dithiocarbamate analogue with potentially decreased ALDH inhibition has copper-dependent proteasome-inhibitory and apoptosis-inducing activity in human breast cancer cells.

Authors:  Fei Wang; Shumei Zhai; Xiaojun Liu; Liwen Li; Shirley Wu; Q Ping Dou; Bing Yan
Journal:  Cancer Lett       Date:  2010-10-29       Impact factor: 8.679

Review 3.  Novel metals and metal complexes as platforms for cancer therapy.

Authors:  Michael Frezza; Sarmad Hindo; Di Chen; Andrew Davenport; Sara Schmitt; Dajena Tomco; Q Ping Dou
Journal:  Curr Pharm Des       Date:  2010-06       Impact factor: 3.116

4.  Membrane Loaded Copper Oleate PEGylated Liposome Combined with Disulfiram for Improving Synergistic Antitumor Effect In Vivo.

Authors:  Lingli Zhou; Liu Yang; Chulei Yang; Yi Liu; Qiuyue Chen; Wenli Pan; Qing Cai; Lifeng Luo; Lu Liu; Shan Jiang; Haibing He; Yu Zhang; Tian Yin; Xing Tang
Journal:  Pharm Res       Date:  2018-05-23       Impact factor: 4.200

Review 5.  New uses for old copper-binding drugs: converting the pro-angiogenic copper to a specific cancer cell death inducer.

Authors:  Di Chen; Q Ping Dou
Journal:  Expert Opin Ther Targets       Date:  2008-06       Impact factor: 6.902

6.  Targeting the ubiquitin-proteasome system for cancer treatment: discovering novel inhibitors from nature and drug repurposing.

Authors:  Claire L Soave; Tracey Guerin; Jinbao Liu; Q Ping Dou
Journal:  Cancer Metastasis Rev       Date:  2017-12       Impact factor: 9.264

7.  Selection and identification of ligand peptides targeting a model of castrate-resistant osteogenic prostate cancer and their receptors.

Authors:  Jami Mandelin; Marina Cardó-Vila; Wouter H P Driessen; Paul Mathew; Nora M Navone; Sue-Hwa Lin; Christopher J Logothetis; Anna Cecilia Rietz; Andrey S Dobroff; Bettina Proneth; Richard L Sidman; Renata Pasqualini; Wadih Arap
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-11       Impact factor: 11.205

8.  Novel 8-hydroxylquinoline analogs induce copper-dependent proteasome inhibition and cell death in human breast cancer cells.

Authors:  Vesna Milacic; Peifu Jiao; Bin Zhang; Bing Yan; Q Ping Dou
Journal:  Int J Oncol       Date:  2009-12       Impact factor: 5.650

9.  Diagnostic biomarkers for renal cell carcinoma: selection using novel bioinformatics systems for microarray data analysis.

Authors:  Adeboye O Osunkoya; Qiqin Yin-Goen; John H Phan; Richard A Moffitt; Todd H Stokes; May D Wang; Andrew N Young
Journal:  Hum Pathol       Date:  2009-08-19       Impact factor: 3.466

10.  Synchrotron X-ray imaging reveals a correlation of tumor copper speciation with Clioquinol's anticancer activity.

Authors:  Raul A Barrea; Di Chen; Thomas C Irving; Q Ping Dou
Journal:  J Cell Biochem       Date:  2009-09-01       Impact factor: 4.429
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.